UNBELIEVABLE: 3 | History Defined

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

Dizal Pharmaceutical shares rose significantly after announcing a major drug rights deal. AstraZeneca will pay $600 million upfront for global rights to Sunvozertinib. This targeted treatment addresses a specific genetic mutation in lung cancer patients. The agreement includes potential future payments tied to development and sales. This collaboration aims to…

The Economic Times · Jul 14

Scientists Discovered a Hidden Immune Backup System That Could Make mRNA Cancer Vaccines Far More Powerful

Washington University researchers found mRNA cancer vaccines activate an unexpected backup immune pathway. The Nature study could help improve vaccines for melanoma, lung cancer, and more.

Medical Daily · Jul 10

Jennifer Grey being comforted by showbiz pals after announcing death of her mother

The Dirty Dancing star is being supported by friends including Richard E. Grant after she took to social media to announce the passing of her mother, Jo Wilder, sharing a heartfelt tribute describing her final days following a recent lung cancer diagnosis.

BANG Premier · Jul 9

Alembic Pharma gets tentative nod from USFDA for generic cancer drug

Alembic Pharmaceuticals has secured tentative approval from the USFDA for its generic Binimetinib tablets. This marks a significant step for the company in the cancer treatment drug market. The approval is for the 45mg strength, with potential for marketing exclusivity. Alembic previously received tentative approval for the 15mg strength. Binimetinib…

The Economic Times · Jun 19

Rural areas lag behind in cancer treatment and prevention – even as rich, urban areas increasingly leave dying from cancer in the rearview

Cancer in the United States experienced a dramatic turnaround in 1991. Prior to that year, cancer deaths had been increasing for decades, peaking at 215 deaths per 100,000 people, meaning about 1 in 4 deaths were attributed to cancer. Then it began to consistently decline, decreasing by 34% between 1991…

The Conversation · Jun 17

Could a Simple Blood Test Stop Lung Cancer Early?

What if a simple blood test could tell you that lung cancer might develop years before it actually appears? It sounds like science fiction, but researchers believe it could soon become reality. A groundbreaking study has identified a unique set of proteins in the blood that may reveal a person's…

MyLifeXP · Jun 16

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

MarketBeat · Jun 11

£20m artificial intelligence tech ‘will speed up cancer diagnosis for millions’ of UK patients

More than four million patients have already received a faster lung cancer diagnosis or all-clear thanks to AI, the government have said

The Independent UK · Jun 10

GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year

The Guardian - UK · Jun 9

GSK to buy US lung cancer drug specialist Nuvalent for £8bn

The acquisition is thought to be GSK’s biggest deal in more than a decade.

Evening Standard · Jun 9